Multidisciplinary treatment of the patient with a severe irritable bowel syndrome

Cover Page

Cite item

Full Text

Abstract

The patient E., aged 39, was described with a severe form of the irritable bowel syndrome that developed after the stress. In addition to the clinical manifestations of IBS, the patient got the somatoform disorders, which manifested itself with a large number of extraintestinal symptoms and led to a disability. According to the recommendations of the Rome Criteria IV 2016, the main medicines for the treatment of biopsychosocial model of IBS are antidepressants. The remission of the disease with a complete recovery of the patient’s disability was achieved by duloxetine, an antidepressant from the group of serotonin and noradrenaline reuptake inhibitors.

About the authors

I. N. Ruchkina

Loginov Moscow Clinical Scientific Practical Center

Email: 207lec@mail.ru

д.м.н., в.н.с. отд. невоспалительной патологии кишечника

Russian Federation, Moscow

A. A. Vyaznikova

Loginov Moscow Clinical Scientific Practical Center

Author for correspondence.
Email: 207lec@mail.ru

м.н.с. лаб. функциональной диагностики заболеваний кишечника

Russian Federation, Moscow

L. K. Indeykina

Loginov Moscow Clinical Scientific Practical Center

Email: 207lec@mail.ru

зав. лаб. функциональной диагностики заболеваний кишечника

Russian Federation, Moscow

D. A. Degterev

Loginov Moscow Clinical Scientific Practical Center

Email: 207lec@mail.ru

к.м.н., зав. неврологическим отд-нием

Russian Federation, Moscow

A. I. Parfenov

Loginov Moscow Clinical Scientific Practical Center

Email: 207lec@mail.ru

д.м.н., проф., зав. отд. патологии кишечника

Russian Federation, Moscow

References

  1. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035
  2. Маев И.В., Черемушкин С.В., Кучерявый Ю.А. Синдром раздраженного кишечника. Римские критерии IV. О роли висцеральной гиперчувствительности и способах ее коррекции. Методическое пособие. М., 2016. 64 с. [Maev IV, Cherjomushkin SV, Kucherjavyj JuA. Irritable bowel syndrome. Rome-IV criteria. The role of visceral hypersensitivity and methods for its correction. Toolkit. Moscow, 2016. 64 p. (In Russ.)].
  3. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. doi: 10.1053/j.gastro.2016.02.031
  4. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93 [Ivashkin VT, Shelygin YuA, Baranskaya EK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-76-93
  5. Liu Y, Zhang L, Wang X, Wang Z, Zhang J, Jiang R, et al. Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression. Clin Gastroenterol Hepatol. 2016;14:1602-11. doi: 10.1016/j.cgh.2016.05.033
  6. Данилов Ан.Б., Данилов Ал.Б. Управление болью. Руководство для врачей различных специальностей. M.: АММ Пресс, 2016 [Danilov AnB, Danilov AlB. Сontrol of pain. A guide for doctors of various specialties. Moscow: AMM Press, 2016 (In Russ.)].
  7. Парфенов А.И., Албулова Е.А., Ручкина И.Н. Синдром раздраженного кишечника в свете Римского консенсуса III (2006 г.): 10 лет спустя. Терапевтический архив. 2016;88(2):4-9 [Parfenov AI, Albulova EA, Ruchkina IN. Irritable bowel syndrome in the light of Rome consensus III (2006): 10 years later. Therapeutic Archive. 2016;88(2):4-9 (In Russ.)]. doi: 10.17116/terarkh20168824-9
  8. Oblizajek NR, Gandhi S, Sharma M, Chakraborty S, Muthyala A, Prichard D, et al. Anorectal pressures measured with high‐resolution manometry in healthy people – Normal values and asymptomatic pelvic floor dysfunction. J Neurogastroenterol Motil. 2019 Jul;31(7):e13597. doi: 10.1111/nmo.13597
  9. Kaplan A, Franzen MD, Nickell PV, Ransom D, Lebovitz PJ. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract. 2014;18(1):11-5. doi: 10.3109/13651501.2013.838632. Epub 2013 Sep 20.
  10. Дюкова Г.М., Погромов А.П., Леонова М.Л. Эффективность антидепрессанта двойного действия в терапии функциональных расстройств желудочно-кишечного тракта. Медицинский совет. 2014;(3):78-80 [Dyukova GM, Pogromov AP, Leonova ML, et al. Effect of the dual action antidepressant duloxetine in the treatment of functional disorders of the gastrointestinal tract. Medical Council. 2014;(3):78-80 (In Russ.)]. doi: 10.21518/2079-701X-2014-4-78-81
  11. Labus JS, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, Naliboff BD. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004 Jul 1;20(1):89-97. doi: 10.1111/j.1365-2036.2004.02007.x

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies